U.S. Markets closed
  • S&P 500

    4,395.26
    -23.89 (-0.54%)
     
  • Dow 30

    34,935.47
    -149.06 (-0.42%)
     
  • Nasdaq

    14,672.68
    -105.59 (-0.71%)
     
  • Russell 2000

    2,226.25
    -13.78 (-0.62%)
     
  • Crude Oil

    73.81
    +0.19 (+0.26%)
     
  • Gold

    1,816.90
    -18.90 (-1.03%)
     
  • Silver

    25.55
    -0.23 (-0.90%)
     
  • EUR/USD

    1.1872
    -0.0024 (-0.2018%)
     
  • 10-Yr Bond

    1.2390
    -0.0300 (-2.36%)
     
  • Vix

    18.24
    +0.54 (+3.05%)
     
  • GBP/USD

    1.3908
    -0.0050 (-0.3547%)
     
  • USD/JPY

    109.6500
    +0.1890 (+0.1727%)
     
  • BTC-USD

    41,717.42
    +75.35 (+0.18%)
     
  • CMC Crypto 200

    955.03
    +5.13 (+0.54%)
     
  • FTSE 100

    7,032.30
    -46.12 (-0.65%)
     
  • Nikkei 225

    27,283.59
    -498.83 (-1.80%)
     

Geron Stock Trading Is Higher On Reinforcing Imetelstat's Approach For Myelofibrosis Treatment, With Data Publication In Journal

·1 min read
  • Geron Corporation (NASDAQ: GERN) stock is trading higher during the premarket in reaction to data publication from the IMbark Phase 2 trial of imetelstat for myelofibrosis (MF) in the Journal of Clinical Oncology.

  • The publication highlights the clinical benefits observed in the study, including symptom response and overall survival, as well as positive biomarker and bone marrow fibrosis assessments, in heavily pre-treated patients.

  • As stated in the paper, IMbark tested two imetelstat doses, and the 9.4 mg/kg dose every three weeks demonstrated clinical benefits.

  • In addition, the reductions in key driver mutations of the disease that were also correlated to clinical benefits suggest the disease-modifying activity of imetelstat.

  • "Targeting the underlying MF malignant clones differentiates imetelstat from other therapeutic agents currently in development for MF," said the lead author of the paper.

  • Currently, the company is conducting IMpactMF Phase 3 trial. It plans to enroll approximately 320 patients with Intermediate-2 or High-risk myelofibrosis who are refractory to prior treatment with a JAK inhibitor, also referred to as refractory MF.

  • The primary endpoint is overall survival. Key secondary endpoints include symptom response, spleen response, progression-free survival, complete response, partial response, clinical improvement, duration of response, safety, pharmacokinetics, and patient-reported outcomes.

  • IMpactMF is currently enrolling patients.

  • Price Action: GERN shares are up 31.9% at $1.86 during the premarket trading session on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.